PIK3CA and ovarian cancer: Indeed, the degree of HR impairment induced by PI3K blockade may vary among different ovarian cancer cells; meanwhile, the sensitivity to dual PARP and PI3K inhibition may be dependent on the degree of concomitant BRCA1/2 downregulation that allows further impairment of DNA damage response/the HR repair process.